NEW YORK (GenomeWeb) – OncoDNA said today that a number of private health insurers, including BUPA Global Insurance, will now reimburse for its OncoStrat&Go testing in the United Kingdom.

OncoStrat&Go is a combined liquid biopsy and tissue test intended to provide a complete genetic profile of a patient's tumor to predict response to targeted, immunotherapeutic, and chemotherapy treatments.

BUPA Global has created a specific code for the reimbursement of the test, while other UK insurers will use a generic code, OncoDNA said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.